What is not working for the company?
What is working for the company?
|Name||Dec 22||Sep 22|
|Mutual Funds (Change:0.22)||15.62%||15.4%|
|Insurance Companies (Change:-0.27)||2.4%||2.67%|
|Other DIIs (Change:0.13)||0.53%||0.4%|
|Non Institution (Change:-0.20)||18.71%||18.91%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in JB CHEMICALS & PHARMACEUTICALS LTD
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of J.B.CHEMICALS & PHARMACEUTICALS LTD. (JBCHEPHARM)?
Can I buy J.B.CHEMICALS & PHARMACEUTICALS LTD. (JBCHEPHARM) shares?
How do I buy J.B.CHEMICALS & PHARMACEUTICALS LTD. (JBCHEPHARM) from Angel One?
- Direct investment: You can buy J.B.CHEMICALS & PHARMACEUTICALS LTD. (JBCHEPHARM) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to J.B.CHEMICALS & PHARMACEUTICALS LTD. (JBCHEPHARM) shares.
In which sector do J.B.CHEMICALS & PHARMACEUTICALS LTD. (JBCHEPHARM) belong?
Today's live share price for JB CHEMICALS & PHARMACEUTICALS LTD is NSE: ₹ 2,031.45, BSE: ₹ 2,034.00 with a current market capitalization of .
Originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals in Dec.'76, J B Chemicals & Pharmaceuticals (JBC) manufactures basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into an MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from Apr.'00. Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines. In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment ie Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new products Cephalosporins, Moviz and its expansion Movi 3D and a nueropsychiatry product through Zephyr for the first time. A 100% EOU manufacturing facility at Panoli for production of Gel,Ointment was commissioned during 2001-02 at a cost of Rs.21 crores and the same was financed through internal accruals. To manufacture 'DOKTOR MOM' lozenges the company is setting up two manufacturing units at Daman at an capital outlay of Rs.28 crores,which is to be financed through internal accruals. The commercial production of the Doktor Mom lozenges at its 100% Export Oriented Unit, started from 1 Sep. 2003 and tablets from 1, Jan. 2004 in Daman.Doktor Mom',the company's brand,was adjudged the Most Trusted European Brand by Reader's Digest in the cold and cough segment for the fourth consecutive year in 2003-04. During 2004-05, the company received approval for its pharmaceutical manufacturing unit from TGA (Australia).During 2004-05, the company plants were approved by US-FDA,TGA-Australia,EDQM, MCC-South Africa, INVIMA(Colombia) and MHRA(UK). During 2004-05, the company is setting up a new facility conforming to international standards in Panoli (Gujarat) to manufacture contrast media products by June 2006. During 2004-05, the company has planned to set up a wholly owned subsidiary in Moscow, Russia, called 'Unique Pharmaceuticals Laboratories' with the intial investment of $ 3 million. During 2005, the company entered into two agreements, one with Pharma-a-Care Pharmaceuticals Pte. Ltd in Australia to develop its niche products in Australian market and another with Ranbaxy Laboratories to enter in the Romanian market. The company has subdivided the value of the share from Rs.10/- per share to Rs.2/- per share with effective from 05, April 2005. During 2005-2006, the company has proposed to amalgamate its wholly owned subsidiary viz. lekar healthcare ltd with itself. The company has fixed April 1, 2006 as the appointed date.Read more